Global Surufatinib Market Growth 2026-2032
The global Surufatinib market size is predicted to grow from US$ 31.21 million in 2025 to US$ 65.39 million in 2032; it is expected to grow at a CAGR of 6.1% from 2026 to 2032.
.In 2025, global surufatinib production reached approximately 12.6 million units.Surufatinib is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of neuroendocrine tumors (NETs). It exerts its effects by simultaneously inhibiting multiple signaling pathways, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), thereby providing dual anti-angiogenic and tumor immune-modulating activities, which suppress tumor growth and the immunosuppressive tumor microenvironment. Surufatinib is characterized by a multi-target synergistic mechanism, convenient oral administration, and broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced neuroendocrine tumors.
Surufatinib, as a multi-target tyrosine kinase inhibitor (TKI), operates within a relatively niche yet growing segment of the neuroendocrine tumor (NET) treatment market. With the increasing detection of NETs due to improved diagnostic methods and the advancement of precision medicine, the demand for targeted therapies continues to rise, providing a stable market foundation for surufatinib.From a competitive landscape perspective, targeted therapies and mTOR inhibitors such as Sunitinib and Everolimus currently dominate the market. However, surufatinib, with its multi-target mechanism acting on VEGFR, FGFR, and CSF-1R, as well as its differentiated advantage in modulating the tumor immune microenvironment, demonstrates competitive potential in specific patient populations.On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, although treatment options for neuroendocrine tumors remain relatively limited, the continuous development of new targeted therapies and immunotherapy regimens is gradually intensifying competition. Therefore, the future market performance of surufatinib will depend on its progress in expanding indications (such as additional NET subtypes or other solid tumors), developing combination treatment strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.
LP Information, Inc. (LPI) ' newest research report, the ?Surufatinib Industry Forecast? looks at past sales and reviews total world Surufatinib sales in 2025, providing a comprehensive analysis by region and market sector of projected Surufatinib sales for 2026 through 2032. With Surufatinib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Surufatinib industry.
This Insight Report provides a comprehensive analysis of the global Surufatinib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Surufatinib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Surufatinib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Surufatinib and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Surufatinib.
This report presents a comprehensive overview, market shares, and growth opportunities of Surufatinib market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Surufatinib market?
What factors are driving Surufatinib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Surufatinib market opportunities vary by end market size?
How does Surufatinib break out by Type, by Application?
.In 2025, global surufatinib production reached approximately 12.6 million units.Surufatinib is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of neuroendocrine tumors (NETs). It exerts its effects by simultaneously inhibiting multiple signaling pathways, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), thereby providing dual anti-angiogenic and tumor immune-modulating activities, which suppress tumor growth and the immunosuppressive tumor microenvironment. Surufatinib is characterized by a multi-target synergistic mechanism, convenient oral administration, and broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced neuroendocrine tumors.
Surufatinib, as a multi-target tyrosine kinase inhibitor (TKI), operates within a relatively niche yet growing segment of the neuroendocrine tumor (NET) treatment market. With the increasing detection of NETs due to improved diagnostic methods and the advancement of precision medicine, the demand for targeted therapies continues to rise, providing a stable market foundation for surufatinib.From a competitive landscape perspective, targeted therapies and mTOR inhibitors such as Sunitinib and Everolimus currently dominate the market. However, surufatinib, with its multi-target mechanism acting on VEGFR, FGFR, and CSF-1R, as well as its differentiated advantage in modulating the tumor immune microenvironment, demonstrates competitive potential in specific patient populations.On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, although treatment options for neuroendocrine tumors remain relatively limited, the continuous development of new targeted therapies and immunotherapy regimens is gradually intensifying competition. Therefore, the future market performance of surufatinib will depend on its progress in expanding indications (such as additional NET subtypes or other solid tumors), developing combination treatment strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.
LP Information, Inc. (LPI) ' newest research report, the ?Surufatinib Industry Forecast? looks at past sales and reviews total world Surufatinib sales in 2025, providing a comprehensive analysis by region and market sector of projected Surufatinib sales for 2026 through 2032. With Surufatinib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Surufatinib industry.
This Insight Report provides a comprehensive analysis of the global Surufatinib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Surufatinib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Surufatinib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Surufatinib and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Surufatinib.
This report presents a comprehensive overview, market shares, and growth opportunities of Surufatinib market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Hospital
- Retail Pharmacy
- Online Pharmacy
- Neuroendocrine Tumor
- Anti-angiogenic Therapy
- Tumor Immune Microenvironment Modulation
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- HUTCHMED
What is the 10-year outlook for the global Surufatinib market?
What factors are driving Surufatinib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Surufatinib market opportunities vary by end market size?
How does Surufatinib break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Surufatinib Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Surufatinib by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Surufatinib by Country/Region, 2021, 2025 & 2032
2.2 Surufatinib Segment by Type
2.2.1 Hospital
2.2.2 Retail Pharmacy
2.2.3 Online Pharmacy
2.2.4 Surufatinib Sales by Type
2.2.4.1 Global Surufatinib Sales Market Share by Type (2021-2026)
2.2.4.2 Global Surufatinib Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Surufatinib Sale Price by Type (2021-2026)
2.3 Surufatinib Segment by Application
2.3.1 Neuroendocrine Tumor
2.3.2 Anti-angiogenic Therapy
2.3.3 Tumor Immune Microenvironment Modulation
2.3.4 Others
2.3.5 Surufatinib Sales by Application
2.3.5.1 Global Surufatinib Sale Market Share by Application (2021-2026)
2.3.5.2 Global Surufatinib Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Surufatinib Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Surufatinib Breakdown Data by Company
3.1.1 Global Surufatinib Annual Sales by Company (2021-2026)
3.1.2 Global Surufatinib Sales Market Share by Company (2021-2026)
3.2 Global Surufatinib Annual Revenue by Company (2021-2026)
3.2.1 Global Surufatinib Revenue by Company (2021-2026)
3.2.2 Global Surufatinib Revenue Market Share by Company (2021-2026)
3.3 Global Surufatinib Sale Price by Company
3.4 Key Manufacturers Surufatinib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Surufatinib Product Location Distribution
3.4.2 Players Surufatinib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SURUFATINIB BY GEOGRAPHIC REGION
4.1 World Historic Surufatinib Market Size by Geographic Region (2021-2026)
4.1.1 Global Surufatinib Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Surufatinib Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Surufatinib Market Size by Country/Region (2021-2026)
4.2.1 Global Surufatinib Annual Sales by Country/Region (2021-2026)
4.2.2 Global Surufatinib Annual Revenue by Country/Region (2021-2026)
4.3 Americas Surufatinib Sales Growth
4.4 APAC Surufatinib Sales Growth
4.5 Europe Surufatinib Sales Growth
4.6 Middle East & Africa Surufatinib Sales Growth
5 AMERICAS
5.1 Americas Surufatinib Sales by Country
5.1.1 Americas Surufatinib Sales by Country (2021-2026)
5.1.2 Americas Surufatinib Revenue by Country (2021-2026)
5.2 Americas Surufatinib Sales by Type (2021-2026)
5.3 Americas Surufatinib Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Surufatinib Sales by Region
6.1.1 APAC Surufatinib Sales by Region (2021-2026)
6.1.2 APAC Surufatinib Revenue by Region (2021-2026)
6.2 APAC Surufatinib Sales by Type (2021-2026)
6.3 APAC Surufatinib Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Surufatinib by Country
7.1.1 Europe Surufatinib Sales by Country (2021-2026)
7.1.2 Europe Surufatinib Revenue by Country (2021-2026)
7.2 Europe Surufatinib Sales by Type (2021-2026)
7.3 Europe Surufatinib Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Surufatinib by Country
8.1.1 Middle East & Africa Surufatinib Sales by Country (2021-2026)
8.1.2 Middle East & Africa Surufatinib Revenue by Country (2021-2026)
8.2 Middle East & Africa Surufatinib Sales by Type (2021-2026)
8.3 Middle East & Africa Surufatinib Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Surufatinib
10.3 Manufacturing Process Analysis of Surufatinib
10.4 Industry Chain Structure of Surufatinib
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Surufatinib Distributors
11.3 Surufatinib Customer
12 WORLD FORECAST REVIEW FOR SURUFATINIB BY GEOGRAPHIC REGION
12.1 Global Surufatinib Market Size Forecast by Region
12.1.1 Global Surufatinib Forecast by Region (2027-2032)
12.1.2 Global Surufatinib Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Surufatinib Forecast by Type (2027-2032)
12.7 Global Surufatinib Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 HUTCHMED
13.1.1 HUTCHMED Company Information
13.1.2 HUTCHMED Surufatinib Product Portfolios and Specifications
13.1.3 HUTCHMED Surufatinib Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 HUTCHMED Main Business Overview
13.1.5 HUTCHMED Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Surufatinib Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Surufatinib by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Surufatinib by Country/Region, 2021, 2025 & 2032
2.2 Surufatinib Segment by Type
2.2.1 Hospital
2.2.2 Retail Pharmacy
2.2.3 Online Pharmacy
2.2.4 Surufatinib Sales by Type
2.2.4.1 Global Surufatinib Sales Market Share by Type (2021-2026)
2.2.4.2 Global Surufatinib Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Surufatinib Sale Price by Type (2021-2026)
2.3 Surufatinib Segment by Application
2.3.1 Neuroendocrine Tumor
2.3.2 Anti-angiogenic Therapy
2.3.3 Tumor Immune Microenvironment Modulation
2.3.4 Others
2.3.5 Surufatinib Sales by Application
2.3.5.1 Global Surufatinib Sale Market Share by Application (2021-2026)
2.3.5.2 Global Surufatinib Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Surufatinib Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Surufatinib Breakdown Data by Company
3.1.1 Global Surufatinib Annual Sales by Company (2021-2026)
3.1.2 Global Surufatinib Sales Market Share by Company (2021-2026)
3.2 Global Surufatinib Annual Revenue by Company (2021-2026)
3.2.1 Global Surufatinib Revenue by Company (2021-2026)
3.2.2 Global Surufatinib Revenue Market Share by Company (2021-2026)
3.3 Global Surufatinib Sale Price by Company
3.4 Key Manufacturers Surufatinib Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Surufatinib Product Location Distribution
3.4.2 Players Surufatinib Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SURUFATINIB BY GEOGRAPHIC REGION
4.1 World Historic Surufatinib Market Size by Geographic Region (2021-2026)
4.1.1 Global Surufatinib Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Surufatinib Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Surufatinib Market Size by Country/Region (2021-2026)
4.2.1 Global Surufatinib Annual Sales by Country/Region (2021-2026)
4.2.2 Global Surufatinib Annual Revenue by Country/Region (2021-2026)
4.3 Americas Surufatinib Sales Growth
4.4 APAC Surufatinib Sales Growth
4.5 Europe Surufatinib Sales Growth
4.6 Middle East & Africa Surufatinib Sales Growth
5 AMERICAS
5.1 Americas Surufatinib Sales by Country
5.1.1 Americas Surufatinib Sales by Country (2021-2026)
5.1.2 Americas Surufatinib Revenue by Country (2021-2026)
5.2 Americas Surufatinib Sales by Type (2021-2026)
5.3 Americas Surufatinib Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Surufatinib Sales by Region
6.1.1 APAC Surufatinib Sales by Region (2021-2026)
6.1.2 APAC Surufatinib Revenue by Region (2021-2026)
6.2 APAC Surufatinib Sales by Type (2021-2026)
6.3 APAC Surufatinib Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Surufatinib by Country
7.1.1 Europe Surufatinib Sales by Country (2021-2026)
7.1.2 Europe Surufatinib Revenue by Country (2021-2026)
7.2 Europe Surufatinib Sales by Type (2021-2026)
7.3 Europe Surufatinib Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Surufatinib by Country
8.1.1 Middle East & Africa Surufatinib Sales by Country (2021-2026)
8.1.2 Middle East & Africa Surufatinib Revenue by Country (2021-2026)
8.2 Middle East & Africa Surufatinib Sales by Type (2021-2026)
8.3 Middle East & Africa Surufatinib Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Surufatinib
10.3 Manufacturing Process Analysis of Surufatinib
10.4 Industry Chain Structure of Surufatinib
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Surufatinib Distributors
11.3 Surufatinib Customer
12 WORLD FORECAST REVIEW FOR SURUFATINIB BY GEOGRAPHIC REGION
12.1 Global Surufatinib Market Size Forecast by Region
12.1.1 Global Surufatinib Forecast by Region (2027-2032)
12.1.2 Global Surufatinib Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Surufatinib Forecast by Type (2027-2032)
12.7 Global Surufatinib Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 HUTCHMED
13.1.1 HUTCHMED Company Information
13.1.2 HUTCHMED Surufatinib Product Portfolios and Specifications
13.1.3 HUTCHMED Surufatinib Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 HUTCHMED Main Business Overview
13.1.5 HUTCHMED Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Surufatinib Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Surufatinib Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Hospital
Table 4. Major Players of Retail Pharmacy
Table 5. Major Players of Online Pharmacy
Table 6. Global Surufatinib Sales by Type (2021-2026) & (Units)
Table 7. Global Surufatinib Sales Market Share by Type (2021-2026)
Table 8. Global Surufatinib Revenue by Type (2021-2026) & ($ million)
Table 9. Global Surufatinib Revenue Market Share by Type (2021-2026)
Table 10. Global Surufatinib Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Oral dosage Form
Table 12. Major Players of Capsules
Table 13. Major Players of Original
Table 14. Major Players of Generic
Table 15. Major Players of 50 mg/capsules
Table 16. Major Players of 100 mg/capsules
Table 17. Global Surufatinib Sale by Application (2021-2026) & (Units)
Table 18. Global Surufatinib Sale Market Share by Application (2021-2026)
Table 19. Global Surufatinib Revenue by Application (2021-2026) & ($ million)
Table 20. Global Surufatinib Revenue Market Share by Application (2021-2026)
Table 21. Global Surufatinib Sale Price by Application (2021-2026) & (US$/Unit)
Table 22. Global Surufatinib Sales by Company (2021-2026) & (Units)
Table 23. Global Surufatinib Sales Market Share by Company (2021-2026)
Table 24. Global Surufatinib Revenue by Company (2021-2026) & ($ millions)
Table 25. Global Surufatinib Revenue Market Share by Company (2021-2026)
Table 26. Global Surufatinib Sale Price by Company (2021-2026) & (US$/Unit)
Table 27. Key Manufacturers Surufatinib Producing Area Distribution and Sales Area
Table 28. Players Surufatinib Products Offered
Table 29. Surufatinib Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global Surufatinib Sales by Geographic Region (2021-2026) & (Units)
Table 33. Global Surufatinib Sales Market Share Geographic Region (2021-2026)
Table 34. Global Surufatinib Revenue by Geographic Region (2021-2026) & ($ millions)
Table 35. Global Surufatinib Revenue Market Share by Geographic Region (2021-2026)
Table 36. Global Surufatinib Sales by Country/Region (2021-2026) & (Units)
Table 37. Global Surufatinib Sales Market Share by Country/Region (2021-2026)
Table 38. Global Surufatinib Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Surufatinib Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Surufatinib Sales by Country (2021-2026) & (Units)
Table 41. Americas Surufatinib Sales Market Share by Country (2021-2026)
Table 42. Americas Surufatinib Revenue by Country (2021-2026) & ($ millions)
Table 43. Americas Surufatinib Sales by Type (2021-2026) & (Units)
Table 44. Americas Surufatinib Sales by Application (2021-2026) & (Units)
Table 45. APAC Surufatinib Sales by Region (2021-2026) & (Units)
Table 46. APAC Surufatinib Sales Market Share by Region (2021-2026)
Table 47. APAC Surufatinib Revenue by Region (2021-2026) & ($ millions)
Table 48. APAC Surufatinib Sales by Type (2021-2026) & (Units)
Table 49. APAC Surufatinib Sales by Application (2021-2026) & (Units)
Table 50. Europe Surufatinib Sales by Country (2021-2026) & (Units)
Table 51. Europe Surufatinib Revenue by Country (2021-2026) & ($ millions)
Table 52. Europe Surufatinib Sales by Type (2021-2026) & (Units)
Table 53. Europe Surufatinib Sales by Application (2021-2026) & (Units)
Table 54. Middle East & Africa Surufatinib Sales by Country (2021-2026) & (Units)
Table 55. Middle East & Africa Surufatinib Revenue Market Share by Country (2021-2026)
Table 56. Middle East & Africa Surufatinib Sales by Type (2021-2026) & (Units)
Table 57. Middle East & Africa Surufatinib Sales by Application (2021-2026) & (Units)
Table 58. Key Market Drivers & Growth Opportunities of Surufatinib
Table 59. Key Market Challenges & Risks of Surufatinib
Table 60. Key Industry Trends of Surufatinib
Table 61. Surufatinib Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Surufatinib Distributors List
Table 64. Surufatinib Customer List
Table 65. Global Surufatinib Sales Forecast by Region (2027-2032) & (Units)
Table 66. Global Surufatinib Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Americas Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 68. Americas Surufatinib Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. APAC Surufatinib Sales Forecast by Region (2027-2032) & (Units)
Table 70. APAC Surufatinib Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Europe Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 72. Europe Surufatinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Middle East & Africa Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 74. Middle East & Africa Surufatinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Global Surufatinib Sales Forecast by Type (2027-2032) & (Units)
Table 76. Global Surufatinib Revenue Forecast by Type (2027-2032) & ($ millions)
Table 77. Global Surufatinib Sales Forecast by Application (2027-2032) & (Units)
Table 78. Global Surufatinib Revenue Forecast by Application (2027-2032) & ($ millions)
Table 79. HUTCHMED Basic Information, Surufatinib Manufacturing Base, Sales Area and Its Competitors
Table 80. HUTCHMED Surufatinib Product Portfolios and Specifications
Table 81. HUTCHMED Surufatinib Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. HUTCHMED Main Business
Table 83. HUTCHMED Latest Developments
Table 1. Surufatinib Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Surufatinib Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Hospital
Table 4. Major Players of Retail Pharmacy
Table 5. Major Players of Online Pharmacy
Table 6. Global Surufatinib Sales by Type (2021-2026) & (Units)
Table 7. Global Surufatinib Sales Market Share by Type (2021-2026)
Table 8. Global Surufatinib Revenue by Type (2021-2026) & ($ million)
Table 9. Global Surufatinib Revenue Market Share by Type (2021-2026)
Table 10. Global Surufatinib Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Oral dosage Form
Table 12. Major Players of Capsules
Table 13. Major Players of Original
Table 14. Major Players of Generic
Table 15. Major Players of 50 mg/capsules
Table 16. Major Players of 100 mg/capsules
Table 17. Global Surufatinib Sale by Application (2021-2026) & (Units)
Table 18. Global Surufatinib Sale Market Share by Application (2021-2026)
Table 19. Global Surufatinib Revenue by Application (2021-2026) & ($ million)
Table 20. Global Surufatinib Revenue Market Share by Application (2021-2026)
Table 21. Global Surufatinib Sale Price by Application (2021-2026) & (US$/Unit)
Table 22. Global Surufatinib Sales by Company (2021-2026) & (Units)
Table 23. Global Surufatinib Sales Market Share by Company (2021-2026)
Table 24. Global Surufatinib Revenue by Company (2021-2026) & ($ millions)
Table 25. Global Surufatinib Revenue Market Share by Company (2021-2026)
Table 26. Global Surufatinib Sale Price by Company (2021-2026) & (US$/Unit)
Table 27. Key Manufacturers Surufatinib Producing Area Distribution and Sales Area
Table 28. Players Surufatinib Products Offered
Table 29. Surufatinib Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global Surufatinib Sales by Geographic Region (2021-2026) & (Units)
Table 33. Global Surufatinib Sales Market Share Geographic Region (2021-2026)
Table 34. Global Surufatinib Revenue by Geographic Region (2021-2026) & ($ millions)
Table 35. Global Surufatinib Revenue Market Share by Geographic Region (2021-2026)
Table 36. Global Surufatinib Sales by Country/Region (2021-2026) & (Units)
Table 37. Global Surufatinib Sales Market Share by Country/Region (2021-2026)
Table 38. Global Surufatinib Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Surufatinib Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Surufatinib Sales by Country (2021-2026) & (Units)
Table 41. Americas Surufatinib Sales Market Share by Country (2021-2026)
Table 42. Americas Surufatinib Revenue by Country (2021-2026) & ($ millions)
Table 43. Americas Surufatinib Sales by Type (2021-2026) & (Units)
Table 44. Americas Surufatinib Sales by Application (2021-2026) & (Units)
Table 45. APAC Surufatinib Sales by Region (2021-2026) & (Units)
Table 46. APAC Surufatinib Sales Market Share by Region (2021-2026)
Table 47. APAC Surufatinib Revenue by Region (2021-2026) & ($ millions)
Table 48. APAC Surufatinib Sales by Type (2021-2026) & (Units)
Table 49. APAC Surufatinib Sales by Application (2021-2026) & (Units)
Table 50. Europe Surufatinib Sales by Country (2021-2026) & (Units)
Table 51. Europe Surufatinib Revenue by Country (2021-2026) & ($ millions)
Table 52. Europe Surufatinib Sales by Type (2021-2026) & (Units)
Table 53. Europe Surufatinib Sales by Application (2021-2026) & (Units)
Table 54. Middle East & Africa Surufatinib Sales by Country (2021-2026) & (Units)
Table 55. Middle East & Africa Surufatinib Revenue Market Share by Country (2021-2026)
Table 56. Middle East & Africa Surufatinib Sales by Type (2021-2026) & (Units)
Table 57. Middle East & Africa Surufatinib Sales by Application (2021-2026) & (Units)
Table 58. Key Market Drivers & Growth Opportunities of Surufatinib
Table 59. Key Market Challenges & Risks of Surufatinib
Table 60. Key Industry Trends of Surufatinib
Table 61. Surufatinib Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Surufatinib Distributors List
Table 64. Surufatinib Customer List
Table 65. Global Surufatinib Sales Forecast by Region (2027-2032) & (Units)
Table 66. Global Surufatinib Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Americas Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 68. Americas Surufatinib Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. APAC Surufatinib Sales Forecast by Region (2027-2032) & (Units)
Table 70. APAC Surufatinib Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Europe Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 72. Europe Surufatinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Middle East & Africa Surufatinib Sales Forecast by Country (2027-2032) & (Units)
Table 74. Middle East & Africa Surufatinib Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Global Surufatinib Sales Forecast by Type (2027-2032) & (Units)
Table 76. Global Surufatinib Revenue Forecast by Type (2027-2032) & ($ millions)
Table 77. Global Surufatinib Sales Forecast by Application (2027-2032) & (Units)
Table 78. Global Surufatinib Revenue Forecast by Application (2027-2032) & ($ millions)
Table 79. HUTCHMED Basic Information, Surufatinib Manufacturing Base, Sales Area and Its Competitors
Table 80. HUTCHMED Surufatinib Product Portfolios and Specifications
Table 81. HUTCHMED Surufatinib Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. HUTCHMED Main Business
Table 83. HUTCHMED Latest Developments
LIST OF FIGURES
Figure 1. Picture of Surufatinib
Figure 2. Surufatinib Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Surufatinib Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Surufatinib Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Surufatinib Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Surufatinib Sales Market Share by Country/Region (2025)
Figure 10. Surufatinib Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Hospital
Figure 12. Product Picture of Retail Pharmacy
Figure 13. Product Picture of Online Pharmacy
Figure 14. Global Surufatinib Sales Market Share by Type in 2026
Figure 15. Global Surufatinib Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Oral dosage Form
Figure 17. Product Picture of Capsules
Figure 18. Product Picture of Original
Figure 19. Product Picture of Generic
Figure 20. Product Picture of 50 mg/capsules
Figure 21. Product Picture of 100 mg/capsules
Figure 22. Surufatinib Consumed in Neuroendocrine Tumor
Figure 23. Global Surufatinib Market: Neuroendocrine Tumor (2021-2026) & (Units)
Figure 24. Surufatinib Consumed in Anti-angiogenic Therapy
Figure 25. Global Surufatinib Market: Anti-angiogenic Therapy (2021-2026) & (Units)
Figure 26. Surufatinib Consumed in Tumor Immune Microenvironment Modulation
Figure 27. Global Surufatinib Market: Tumor Immune Microenvironment Modulation (2021-2026) & (Units)
Figure 28. Surufatinib Consumed in Others
Figure 29. Global Surufatinib Market: Others (2021-2026) & (Units)
Figure 30. Global Surufatinib Sale Market Share by Application (2025)
Figure 31. Global Surufatinib Revenue Market Share by Application in 2025
Figure 32. Surufatinib Sales by Company in 2025 (Units)
Figure 33. Global Surufatinib Sales Market Share by Company in 2025
Figure 34. Surufatinib Revenue by Company in 2025 ($ millions)
Figure 35. Global Surufatinib Revenue Market Share by Company in 2025
Figure 36. Global Surufatinib Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Surufatinib Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Surufatinib Sales 2021-2026 (Units)
Figure 39. Americas Surufatinib Revenue 2021-2026 ($ millions)
Figure 40. APAC Surufatinib Sales 2021-2026 (Units)
Figure 41. APAC Surufatinib Revenue 2021-2026 ($ millions)
Figure 42. Europe Surufatinib Sales 2021-2026 (Units)
Figure 43. Europe Surufatinib Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Surufatinib Sales 2021-2026 (Units)
Figure 45. Middle East & Africa Surufatinib Revenue 2021-2026 ($ millions)
Figure 46. Americas Surufatinib Sales Market Share by Country in 2025
Figure 47. Americas Surufatinib Revenue Market Share by Country (2021-2026)
Figure 48. Americas Surufatinib Sales Market Share by Type (2021-2026)
Figure 49. Americas Surufatinib Sales Market Share by Application (2021-2026)
Figure 50. United States Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Surufatinib Sales Market Share by Region in 2025
Figure 55. APAC Surufatinib Revenue Market Share by Region (2021-2026)
Figure 56. APAC Surufatinib Sales Market Share by Type (2021-2026)
Figure 57. APAC Surufatinib Sales Market Share by Application (2021-2026)
Figure 58. China Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 62. India Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Surufatinib Sales Market Share by Country in 2025
Figure 66. Europe Surufatinib Revenue Market Share by Country (2021-2026)
Figure 67. Europe Surufatinib Sales Market Share by Type (2021-2026)
Figure 68. Europe Surufatinib Sales Market Share by Application (2021-2026)
Figure 69. Germany Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 70. France Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Surufatinib Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Surufatinib Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Surufatinib Sales Market Share by Application (2021-2026)
Figure 77. Egypt Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Surufatinib in 2026
Figure 83. Manufacturing Process Analysis of Surufatinib
Figure 84. Industry Chain Structure of Surufatinib
Figure 85. Channels of Distribution
Figure 86. Global Surufatinib Sales Market Forecast by Region (2027-2032)
Figure 87. Global Surufatinib Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Surufatinib Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Surufatinib Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Surufatinib Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Surufatinib Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Surufatinib
Figure 2. Surufatinib Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Surufatinib Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Surufatinib Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Surufatinib Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Surufatinib Sales Market Share by Country/Region (2025)
Figure 10. Surufatinib Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Hospital
Figure 12. Product Picture of Retail Pharmacy
Figure 13. Product Picture of Online Pharmacy
Figure 14. Global Surufatinib Sales Market Share by Type in 2026
Figure 15. Global Surufatinib Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Oral dosage Form
Figure 17. Product Picture of Capsules
Figure 18. Product Picture of Original
Figure 19. Product Picture of Generic
Figure 20. Product Picture of 50 mg/capsules
Figure 21. Product Picture of 100 mg/capsules
Figure 22. Surufatinib Consumed in Neuroendocrine Tumor
Figure 23. Global Surufatinib Market: Neuroendocrine Tumor (2021-2026) & (Units)
Figure 24. Surufatinib Consumed in Anti-angiogenic Therapy
Figure 25. Global Surufatinib Market: Anti-angiogenic Therapy (2021-2026) & (Units)
Figure 26. Surufatinib Consumed in Tumor Immune Microenvironment Modulation
Figure 27. Global Surufatinib Market: Tumor Immune Microenvironment Modulation (2021-2026) & (Units)
Figure 28. Surufatinib Consumed in Others
Figure 29. Global Surufatinib Market: Others (2021-2026) & (Units)
Figure 30. Global Surufatinib Sale Market Share by Application (2025)
Figure 31. Global Surufatinib Revenue Market Share by Application in 2025
Figure 32. Surufatinib Sales by Company in 2025 (Units)
Figure 33. Global Surufatinib Sales Market Share by Company in 2025
Figure 34. Surufatinib Revenue by Company in 2025 ($ millions)
Figure 35. Global Surufatinib Revenue Market Share by Company in 2025
Figure 36. Global Surufatinib Sales Market Share by Geographic Region (2021-2026)
Figure 37. Global Surufatinib Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Surufatinib Sales 2021-2026 (Units)
Figure 39. Americas Surufatinib Revenue 2021-2026 ($ millions)
Figure 40. APAC Surufatinib Sales 2021-2026 (Units)
Figure 41. APAC Surufatinib Revenue 2021-2026 ($ millions)
Figure 42. Europe Surufatinib Sales 2021-2026 (Units)
Figure 43. Europe Surufatinib Revenue 2021-2026 ($ millions)
Figure 44. Middle East & Africa Surufatinib Sales 2021-2026 (Units)
Figure 45. Middle East & Africa Surufatinib Revenue 2021-2026 ($ millions)
Figure 46. Americas Surufatinib Sales Market Share by Country in 2025
Figure 47. Americas Surufatinib Revenue Market Share by Country (2021-2026)
Figure 48. Americas Surufatinib Sales Market Share by Type (2021-2026)
Figure 49. Americas Surufatinib Sales Market Share by Application (2021-2026)
Figure 50. United States Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 51. Canada Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 52. Mexico Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 53. Brazil Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 54. APAC Surufatinib Sales Market Share by Region in 2025
Figure 55. APAC Surufatinib Revenue Market Share by Region (2021-2026)
Figure 56. APAC Surufatinib Sales Market Share by Type (2021-2026)
Figure 57. APAC Surufatinib Sales Market Share by Application (2021-2026)
Figure 58. China Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 59. Japan Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 60. South Korea Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 61. Southeast Asia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 62. India Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 63. Australia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 64. China Taiwan Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 65. Europe Surufatinib Sales Market Share by Country in 2025
Figure 66. Europe Surufatinib Revenue Market Share by Country (2021-2026)
Figure 67. Europe Surufatinib Sales Market Share by Type (2021-2026)
Figure 68. Europe Surufatinib Sales Market Share by Application (2021-2026)
Figure 69. Germany Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 70. France Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 71. UK Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 72. Italy Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 73. Russia Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 74. Middle East & Africa Surufatinib Sales Market Share by Country (2021-2026)
Figure 75. Middle East & Africa Surufatinib Sales Market Share by Type (2021-2026)
Figure 76. Middle East & Africa Surufatinib Sales Market Share by Application (2021-2026)
Figure 77. Egypt Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 78. South Africa Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 79. Israel Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 80. Turkey Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 81. GCC Countries Surufatinib Revenue Growth 2021-2026 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Surufatinib in 2026
Figure 83. Manufacturing Process Analysis of Surufatinib
Figure 84. Industry Chain Structure of Surufatinib
Figure 85. Channels of Distribution
Figure 86. Global Surufatinib Sales Market Forecast by Region (2027-2032)
Figure 87. Global Surufatinib Revenue Market Share Forecast by Region (2027-2032)
Figure 88. Global Surufatinib Sales Market Share Forecast by Type (2027-2032)
Figure 89. Global Surufatinib Revenue Market Share Forecast by Type (2027-2032)
Figure 90. Global Surufatinib Sales Market Share Forecast by Application (2027-2032)
Figure 91. Global Surufatinib Revenue Market Share Forecast by Application (2027-2032)
